Sort   by:  
 Page size 
TranscriptomicsGenome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in Glioblastoma stem-like cells
To identify new therapeutic targets for Glioblastoma (GBM), we performed genome-wide CRISPR-Cas9 "knockout" (KO) screens in patient-derived GBM stem-like cells (GSCs) and human neural stem/progenitors (NSCs), non-neoplastic stem cell controls, for genes required for their in vitro growth. ...
ORGANISM(S): Homo sapiens 
2016-02-15 | E-GEOD-70038 | biostudies-arrayexpress
ProteomicsDiscovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation
PKMYT1 has recently emerged as a compelling therapeutic target for precision cancer therapy due to its synthetic lethality with oncogenic alterations such as CCNE1 amplification and mutations in FBXW7 and PPP2R1A. Current small molecule PKMYT1 inhibitors face limitations, such as insufficient molecu...
ORGANISM(S): Homo sapiens (Human) 
2025-09-28 | PXD062889 | Pride
Protac Pkmyt1 Synthetic lethality Ai-generation 
GenomicsTargeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer
Targeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer
PRJNA1193988 | ENA
GenomicsTargeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer.
Targeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer.
PRJNA1412541 | ENA
GenomicsTargeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer [scRNA-seq]
Targeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer [scRNA-seq]
PRJNA1200032 | ENA
TranscriptomicsTargeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer
Although immunotherapy has been successful in various tumors, its efficacy in castration resistant prostate cancer (CRPC) is minimal, due to reduced presence of intratumoral immune effector cells in CRPC. How CRPC cells escape immune surveillance is not fully defined. Here we demonstrate that PKMYT1...
ORGANISM(S): Homo sapiens 
2026-02-11 | GSE283458 | GEO
TranscriptomicsTargeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer.
Although immunotherapy has been successful in various tumors, its efficacy in castration resistant prostate cancer (CRPC) is minimal, due to reduced presence of intratumoral immune effector cells in CRPC. How CRPC cells escape immune surveillance is not fully defined. Here we demonstrate that PKMYT1...
ORGANISM(S): Mus musculus 
2026-02-11 | GSE317406 | GEO
TranscriptomicsTargeting PKMYT1 enhances antitumor immune responses in castration-resistant prostate cancer [scRNA-seq]
Although immunotherapy has been successful in various tumors, its efficacy in castration resistant prostate cancer (CRPC) is minimal, due to reduced presence of intratumoral immune effector cells in CRPC. How CRPC cells escape immune surveillance is not fully defined. Here we demonstrate that PKMYT1...
ORGANISM(S): Mus musculus 
2026-02-11 | GSE284679 | GEO
UnknownPKMYT1 kinase ameliorates cisplatin sensitivity in osteosarcoma.
Not available
S-EPMC12092789 | biostudies-literature
UnknownStructure-based virtual screening discovers novel PKMYT1 inhibitors.
Not available
S-EPMC11411631 | biostudies-literature
Sort   by:  
 Page size